- The process of creating a drug - May 23, 2023
- How do scientists model mental disorders in animals? - May 23, 2023
Abstract
5-Methoxy-N-methyl-N-isopropyltryptamine, commonly referred to as 5-MeO-MiPT or moxy, is a relatively obscure psychedelic compound belonging to the tryptamine family. Chemically, it is related to other tryptamines such as 5-MeO-DMT and 5-MeO-DiPT. Its psychoactive effects arise from its interaction with serotonin receptors in the brain. The initial synthesis and pharmacological profile of 5-MeO-MiPT were documented in 1985 by researchers David Repke and Alexander Shulgin.
This article presents a comprehensive overview of 5-MeO-MiPT, including its general information, physico-chemical properties, pharmacology in recreational use, effects and symptoms, use street names, prices and approximate dosage, dangerous interactions, legal status, synthesis of 5-MeO-MiPT, conclusion, and bibliography.
5-MeO-MiPT: What We Know
General Information About 5-MeO-MiPT [1-4]
Other synonyms names of 5-MeO-MiPT are: 5-Methoxy-N-methyl-N-isopropyltryptamine; N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-N-methylpropan-2-amine; 5-methoxy-N-methyl-N-(1-methylethyl)-1H-Indole-3-ethanamine; N-(2-(5-Methoxy-1H-indol-3-yl)ethyl)-N-methylpropan-2-amine; 5-methoxy MiPT
IUPAC Name of 5-MeO-MiPT: N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-N-methylpropan-2-amine
CAS numbers is 96096-55-8
Trade names are Moxy
Physico-Chemical Properties of 5-MeO-MiPT [1-4, 8]
- Molecular Formula C15H22N2O
- Molar Weight 246.35 g/mol
- Boiling point 390.3 ℃
- Melting Point 162–163 °C
- Flash Point: 189.9 °C
- Solubility: DMF: 30 mg/ml; DMSO: 30 mg/ml; Ethanol: 30 mg/ml; Ethanol:PBS(pH 7.2) (1:1): 0.5 mg/ml; Methanol: 1 mg/ml
- Color/Form: crystalline solid
Structural formula present on Figure 1.

Figure 1. Structure of 5-MeO-MiPT
Powder and tablet possible of the 5-MeO-MiPT can be seen in the pictures provided in Figure 2 and Figure 3.

Figure 2. Powder of 5-MeO-MiPT

Figure 3. Tablets of 5-MeO-MiPT
General Information of 5-MeO-MiPT in Recreational Use and Pharmacology [1-7]
The psychedelic effects of 5-MeO-MiPT are thought to arise primarily from its role as a partial agonist at the 5-HT2A receptor, which is well-known for its involvement in the psychedelic experience. In addition to this, there are suggestions that it may inhibit monoamine oxidase (MAO), digestive enzymes that play a role in neurotransmitter breakdown. However, this mechanism remains unproven in scientific studies.
Interestingly, while 5-MeO-MiPT shows a strong affinity for 5-HT1A receptors, it also binds effectively to the serotonin transporter (SERT) and norepinephrine transporter (NET). This action classifies it as a moderately potent serotonin-norepinephrine reuptake inhibitor (SNRI). Such properties might explain the numerous anecdotal accounts of its antidepressant and anxiolytic effects at lower doses.
To illustrate, many people are familiar with SNRIs like venlafaxine, which are often prescribed to combat depression. Similarly, buspirone, a 5-HT1A agonist, is typically used to address anxiety. These comparisons highlight the potential therapeutic avenues that compounds like 5-MeO-MiPT might offer, suggesting that even modest doses could yield significant emotional benefits for some users.
Effects and symptoms of 5-MeO-MiPT Use [1, 5]
5-MeO-MiPT is an analogue of the more well-known substance 5-MeO-DiPT, often referred to as “foxy methoxy,” and is colloquially called “moxy.” Some users have noted that it offers the tactile sensations associated with 5-MeO-DiPT while minimizing certain adverse effects. At higher doses, its psychedelic properties become more pronounced, with comparisons made to 5-MeO-DMT. Users typically report that doses between 4 and 10 milligrams provide a euphoric and tactile experience, with significant energy effects that can notably elevate heart rates.
Sensory perceptions may become heightened to the extent that synesthesia occurs, allowing users to “touch” or “taste” sounds. 5-MeO-MiPT can be consumed orally or smoked, with oral ingestion leading to more pronounced visual and sensory effects. The experience can be divided into two phases: the first phase is stimulating and entactogenic, while the latter resembles the effects of traditional tryptamine psychedelics like psilocybin or LSD. When smoked, the stimulating effects—both physical and cognitive—tend to be more accentuated.
Additionally, the FDA and the European Medicines Agency have approved a Phase 1 clinical trial involving human participants, indicating growing interest in the potential therapeutic applications of this compound.
All effects in different categories [5]
Physical effects
Stimulation – At doses below 10 to 15mg, 5-MeO-MiPT produces a degree of stimulation comparable to that of LSD.
- Spontaneous bodily sensations – The “body high” of 5-MeO-MiPT can be described as a pleasurable, warm, soft and all-encompassing glow. This may be accompanied by a cold, sharp tingling sensation that manifests spontaneously at different unpredictable points throughout the experience, although for others can maintain a consistent presence that steadily rises with the onset and hits its limit once the peak has been reached.
- Nausea – Nausea is commonly reported and can sometimes result in vomiting, although it typically fades after the come up phase. In comparison to 5-MeO-DiPT, this substance has a much lower tendency to trigger unpleasant physical reactions.
- Bodily pressures
- Abnormal heartbeat
- Increased heart rate
- Increased blood pressure
- Headaches
- Dehydration
- Stomach bloating – At higher doses, this compound can induce severe stomach bloating within those who are susceptible. This can be partially to fully mitigated through the use of antacids.
- Pupil dilation
- Vasoconstriction
- Diarrhea
Visual effects
- Enhancements
- Colour enhancement
- Pattern recognition enhancement
- Visual acuity enhancement
- Distortions
- Drifting (Melting, Breathing, Warping and Flowing) – In comparison to other psychedelics, this effect can be described as highly detailed, slow and smooth in motion and static in appearance.
- Tracers
- After images
- Symmetrical texture repetition
- Colour shifting
- Scenery slicing
- Geometry
- The visual geometry produced by 5-MeO-MiPT can be described as more similar in appearance to that of Psilocin, 4-AcO-DMT or ayahuasca than that of LSD or 2C-B. It can be comprehensively described through its variations as intricate in complexity, abstract in form, organic in feel, brightly lit, multicoloured in scheme, glossy in shading, equal in blurred and sharp edges, large in size, fast in speed, smooth in motion, equal in rounded and angular corners, non-immersive in depth and progressive in intensity. At higher dosages they are significantly more likely to result in states of level 8B visual geometry over level 8A.
- Hallucinatory states
- 5-MeO-MiPT produces a full range of high level hallucinatory states in a fashion that is more consistent and reproducible than that of many other commonly used psychedelics.
- Transformations
- Internal hallucination (autonomous entities; settings, sceneries, and landscapes; perspective hallucinations and scenarios and plots) – In comparison to other psychedelics such as LSD, 5-MeO-MiPT is extremely high in hallucinations at appropriate dosages. These are more common in darkness and can be comprehensibly described through their variations as lucid in believability, interactive in style, new experiences in content, autonomous in controllability, geometry-based in style and almost exclusively of a personal, religious, spiritual, science-fiction, fantasy, surreal, nonsensical or transcendental nature in their overall theme.
Cognitive effects
- At low to moderate doses, the cognitive effects of 5-MeO-MiPT are often described by many as both insightful and moderately relaxing, but at some points quite stimulating. 5-MeO-MiPT produces a large number of typical psychedelic cognitive effects which progressively intensify proportional to dosage. At higher dosages, however, it becomes primarily sedating and impairing with depersonalization and no accompanying insight.
- Analysis enhancement
- Empathy, affection, and sociability enhancement – This effect is consistently manifested only in the context of social settings in which one is within the company of others. These feelings of sociability, love and empathy are a little weaker and less sharp than those found on substances such as MDMA and 2C-B but still prove strong enough to provide long-lasting therapeutic effects.
- Depersonalization – Unlike most traditional psychedelics, 5-MeO-MiPT can cause extreme depersonalization and dissociation for some users throughout the duration of the experience.
- Conceptual thinking
- Increased music appreciation
- Emotion enhancement
- Increased libido
- Memory suppression
- Novelty enhancement
- Personal bias suppression
- Thought acceleration
- Thought connectivity
- Time distortion
- Wakefulness
Auditory effects
- Enhancements
- Distortions
- Hallucinations
Street Names, Prices and Approximate Dosage [1, 5]
5-Methoxy-N-methyl-N-isopropyltryptamine, commonly referred to as 5-MeO-MiPT or simply “moxy,” is available in various forms, including pellets priced at €49.95 for 10 mg and €199.95 for 50 mg.
Dosage Guidelines
- Threshold: 3 mg
- Light Dose: 3 – 7 mg
- Common Dose: 7 – 15 mg
- Strong Dose: 15 – 20 mg
- Heavy Dose: 20 mg and above
Duration of Effects
- Total Duration: 5 – 8 hours
- Onset Time: 20 – 40 minutes
- Come-Up Time: 30 – 60 minutes
- Peak Effects: 2 – 3 hours
- Offset: 2 – 3 hours
- After Effects: 2 – 4 hours
Dangerous interactions [5]
- 2C-T-X – Both classes of compounds can be unpredictable alone.
- 2C-X – The 5-MeO psychedelics can interact unpredictably to potentiate other psychedelics.
- Cannabis – May increase the risk of negative psychological effects such as anxiety, paranoia, and psychosis.
- DOx – The 5-MeO class of tryptamines can be unpredictable in their interactions, particularly increasing the risk of unpleasant physical side effects.
- MDMA – Some of the 5-MeO tryptamines are a bit unpredictable and should be mixed with MDMA with care.
- Mescaline – The 5-MeO class of tryptamines can be unpredictable in their interactions.
- NBOMe – The 5-MeO class of tryptamines can be unpredictable in their interactions and the NBOMes are known to be unpredictable even alone. This combination is best avoided.
- Amphetamines – The anxiogenic and focusing effects of stimulants increase the chance of unpleasant thought loops. The combination is generally unnecessary because of the stimulating effects of psychedelics.
- Cocaine – The anxiogenic and focusing effects of stimulants increase the chance of unpleasant thought loops. The combination is generally unnecessary because of the stimulating effects of psychedelics.
- DXM – Little information exists about this combination.
- Tramadol – Increased risk of serotonin syndrome.
- aMT – Increased risk of serotonin syndrome.
- MAOIs – Increased risk of serotonin syndrome.
- PCP – Little information exists about this combination. May increase risk of psychosis and excessive stimulation.
Synthesis of 5-MeO-MiPT [8]
To a solution of 5-methoxy-N-methyltryptamine (5-MeO-NMT) in methanol there was added acetone and 10% Pd/C. This mixture was shaken under a hydrogen atmosphere at 50 psi for 15 h. The catalyst was removed by filtration through a bed of Celite, the filtrate stripped of solvent under vacuum, and the solid residue recrystallized from Et2O/hexane to give N-isopropyl-5-methoxy-N-methyl-tryptamine (5-MeO-MIPT). This was isolated as the hydrochloride salt by dissolving it in a small amount of IPA, neutralization with concentrated HCl, and dilution with Et2O.
Synthesis of 5-MeO-MiPT starting from 5-MeO-NMT and according to the scheme Figure 4.

Figure 4. General scheme of 5-MeO-MiPT synthesis
Legal Status [1, 5]
- Austria: Under the NPSG (New Psychoactive Substances Act), the possession, production, and sale of 5-MeO-MiPT is prohibited. However, individuals caught without intent to distribute may not face prosecution.
- Brazil: 5-MeO-MiPT is illegal to produce, sell, or possess, as it is included in Portaria SVS/MS n 344.
- China: Classified as a Category I psychotropic substance, 5-MeO-MiPT is illegal to sell, purchase, import, export, or manufacture.
- Finland: The substance has been banned in Finland since December 2014.
- Germany: As of July 18, 2019, 5-MeO-MiPT is regulated under the NpSG (New Psychoactive Substances Act). While possession is illegal, it is not punishable. However, the production, importation, distribution, and sale are criminal offenses.
- Japan: 5-MeO-MiPT is designated as a “Shitei-Yakubutsu” (Designated Substance) under the Pharmaceutical Affairs Law, rendering it illegal to possess or sell.
- Latvia: The substance is classified as a Schedule I drug.
- Luxembourg: 5-MeO-MiPT is not listed among prohibited substances, which means it remains legal.
- New Zealand: As an analogue of DMT, 5-MeO-MiPT is classified as a Class C controlled drug.
- Romania: Since January 2011, 5-MeO-MiPT and its derivatives have been illegal.
- Switzerland: 5-MeO-MiPT is specifically listed as a controlled substance under Verzeichnis E.
- Turkey: The substance is classified as a drug and is illegal to possess, manufacture, supply, or import.
- United Kingdom: 5-MeO-MiPT is categorized as a Class A drug, being an ether of 5-HO-MiPT, which falls under the Class A classification due to the tryptamine catch-all provision.
- United States: In the U.S., 5-MeO-MiPT is not scheduled. However, it may be considered an analogue of the Schedule I substance 5-MeO-DiPT under the Controlled Substances Act, which could lead to prosecution under the Federal Analogue Act for sales intended for human consumption or illegal uses.
- Florida: In Florida, 5-MeO-MiPT is classified as a Schedule I drug.
- Louisiana: As of June 2013, 5-MeO-MiPT is classified as a Schedule I substance.
- Minnesota: The state has included 5-MeO-MiPT in a series of banned substances.
Conclusion
The analysis of 5-MeO-MiPT highlights its unique psychoactive effects, potential therapeutic applications, and complex legal status.
Psychoactive Effects: Users report euphoric and tactile experiences, particularly at moderate doses, making it an intriguing substance for psychedelic exploration.
Dosage and Experience: Clear dosage guidelines suggest that small amounts can elicit significant effects, with experiences divided into stimulating and traditional psychedelic phases.
Potential Therapeutic Applications: Anecdotal evidence indicates possible antidepressant and anxiolytic effects, pointing to its potential in mental health treatment and the need for further research.
Legal Landscape: The inconsistent legal status across countries underscores the ongoing debate about regulating psychoactive substances and highlights the need for informed policies.
Need for Research: Further studies are essential to clarify the pharmacology and safety profile of 5-MeO-MiPT, which could enhance understanding of its role in the therapeutic landscape.
Overall, 5-MeO-MiPT presents an interesting area for exploration, combining unique effects with important implications for future research and regulation.
Bibliography
- https://en.wikipedia.org/wiki/5-MeO-MiPT
- https://pubchem.ncbi.nlm.nih.gov/compound/2763156
- https://www.chemspider.com/Chemical-Structure.2043845.html
- https://www.caymanchem.com/product/11482
- https://psychonautwiki.org/wiki/5-MeO-MiPT
- https://erowid.org/chemicals/5meo_mipt/5meo_mipt.shtml
- https://www.bluelight.org/community/threads/the-big-dandy-5-meo-mipt-thread.100105/\
- https://isomerdesign.com/pihkal/read/tk/40